Revolution Med (RVMD) Priced Rasonque at $39,800 per 30-Day Supply. Can Access Match the Clinical Breakthrough?
Revolution Medicines, Inc. (NASDAQ:RVMD) received FDA approval for Rasonque, or daraxonrasib, following an expedited review.
Revolution Medicines Inc. (RVMD)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Farallon Capital Thomas Steyer | 13,550,796 | $2,537,793,075 | -1% | 11.71% |
| 2. | Baker Bros. Advisors Julian Baker And Felix Baker | 11,443,357 | $2,143,111,899 | +20% | 10.74% |
| 3. | Darwin Global Management Abhishek Trehan | 10,629,822 | $2,047,516,314 | +381% | 54.45% |
| 4. | Paradigm Biocapital Advisors Senai Asefaw | 6,361,323 | $1,191,348,571 | -5% | 22.31% |
| 5. | Biotechnology Value Fund / BVF Inc Mark Lampert | 2,965,160 | $555,315,165 | +4% | 14.2% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $46.00 | 760,869 | $34,999,974.00 | 760,869 | 2024-12-05 | Filing | |
| $46.00 | 543,478 | $24,999,988.00 | 2,096,612 | 2024-12-05 | Filing | |
| $20.85 | 6,200 | $129,270.00 | 1,553,134 | 2023-03-10 | Filing | |
| $20.43 | 93,800 | $1,916,334.00 | 1,546,934 | 2023-03-10 | Filing | |
| $22.00 | 318,181 | $6,999,982.00 | 618,181 | 2023-03-07 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $206.15 | 625 | $128,846.25 | 17,090 | 2026-08-31 | Filing | |
| $205.19 | 2,128 | $436,639.85 | 17,715 | 2026-08-31 | Filing | |
| $204.35 | 7,271 | $1,485,829.58 | 19,843 | 2026-08-31 | Filing | |
| $203.55 | 26,160 | $5,324,823.53 | 27,114 | 2026-08-31 | Filing | |
| $202.48 | 12,919 | $2,615,863.67 | 53,274 | 2026-08-31 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,695,790 | $2,564,947,573 | 0.04% | |
| 2. | 12,200,422 | $2,284,894,993 | 0.1% | |
| 3. | 10,736,145 | $2,010,360,348 | 0.82% | |
| 4. | 9,088,661 | $1,702,124,432 | 0.04% | |
| 5. | 8,294,855 | $1,553,460,444 | 0.07% |
News See All
Incyte Corporation (INCY) vs. Revolution Medicines (RVMD): Which Biotech Stock Offers the Better KRAS Opportunity?
Incyte Corporation (NASDAQ:INCY) generated buzz on August 19 when RBC Capital highlighted upcoming ESMO data for its KRAS G12D inhibitor ‘734 in combination with mFOLFIRINOX and GemNabP.
Revolution Medicines Stock (RVMD) Gets Price Target Hike on New Revenue-Generating Cancer Drug
Shares in oncology drugs group Revolution Medicines ($RVMD) were healthier again today after a leading analyst said its new pancreatic cancer drug ...
Revolution Medicines Stock (RVMD) Boosted By FDA Pancreatic Cancer Approval
Shares in oncology drugs group Revolution Medicines ($RVMD) were higher today after the U.S. Food and Drug Administration approved its treatment fo...
Is BeOne Medicines AG (ONC) Deal With Revolution Medicines (RVMD) a Win-Win for Both Companies?
Two oncology powerhouses, BeOne Medicines AG (NASDAQ:ONC) and Revolution Medicines, Inc. (NASDAQ:RVMD), announced a major multi-part clinical collaboration and regional licensing deal.
Can Revolution Medicines (RVMD) Turn A New Ally Into Global Reach?
Revolution Medicines (NASDAQ:RVMD) just picked up a partner with deep pockets and a presence across Asia.
Could Revolution Medicines (RVMD) Become a $20 Billion Cancer Drug Story?
Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here.
10 Best Hot Stocks to Buy for June
In this article, we will discuss the 10 Best Hot Stocks to Buy for June. The volatility in global markets is yet again in the spotlight, with stocks pulling back from all-time highs.
10 Best Non-AI Stocks to Buy According to Billionaire Stanley Druckenmiller
In this article, we will discuss the 10 Best Non-AI Stocks to Buy According to Billionaire Stanley Druckenmiller.
Hedge Fund Resource Center